Blueprint
FORM 6-K
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Report
of Foreign Issuer
Pursuant
to Rule 13a-16 or 15d-16 of
the
Securities Exchange Act of 1934
For the
month of October
2018
Commission
File Number: 001-11960
AstraZeneca PLC
1
Francis Crick Avenue
Cambridge
Biomedical Campus
Cambridge
CB2 0AA
United
Kingdom
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F X Form 40-F __
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1):
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ______
Indicate
by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information
to the Commission pursuant to Rule 12g3-2(b) under the Securities
Exchange Act of 1934.
Yes __
No X
If
“Yes” is marked, indicate below the file number
assigned to the Registrant in connection with Rule 12g3-2(b):
82-_____________
AstraZeneca PLC
INDEX
TO EXHIBITS
1.
Additional
financial information-Grünenthal deal
31 October 2018 09:45 GMT
Additional financial information in respect of the
previously-
announced agreement with Grünenthal for rights to
Nexium in Europe and Vimovo worldwide (ex-US)
Pursuant to Listing Rule 10.4.1R (notification of class 2
transactions), AstraZeneca provides the following additional
financial information in respect of the
previously-announced agreement with Grünenthal for rights
to Nexium in Europe and Vimovo worldwide (ex-US). The announcement of the
agreement was initially released at 07:00 GMT on 30 October
2018.
The book value of gross assets subject to the divestments was
approximately $99 million at 31 December 2017. In the year to 31
December 2017 the aggregate pre-tax profits attributable
to Nexium and Vimovo in the relevant territories were $203
million. The consideration will be satisfied in cash and the
proceeds used for general corporate purposes.
About AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company that
focuses on the discovery, development and commercialisation of
prescription medicines, primarily for the treatment of diseases in
three therapy areas - Oncology, Cardiovascular, Renal &
Metabolism and Respiratory. AstraZeneca operates in over 100
countries and its innovative medicines are used by millions of
patients worldwide. For more information, please
visit www.astrazeneca.com and
follow us on Twitter @AstraZeneca.
Media
Relations
|
|
|
Karen
Birmingham
|
UK/Global
|
+44 203
749 5634
|
Rob
Skelding
|
UK/Global
|
+44 203
749 5821
|
Matt
Kent
|
UK/Global
|
+44 203
749 5906
|
Gonzalo
Viña
|
UK/Global
|
+44 203
749 5916
|
Jennifer
Hursit
|
UK/Global
|
+44 203
749 5762
|
Jacob
Lund
|
Sweden
|
+46 8
553 260 20
|
Michele
Meixell
|
US
|
+1 302
885 2677
|
|
|
|
Investor
Relations
|
|
|
Thomas
Kudsk Larsen
|
|
+44 203
749 5712
|
Henry
Wheeler
|
Oncology
|
+44 203
749 5797
|
Christer
Gruvris
|
Cardiovascular;
Metabolism
|
+44 203
749 5711
|
Nick
Stone
|
Respiratory;
Renal
|
+44 203
749 5716
|
Josie
Afolabi
|
Other
|
+44 203
749 5631
|
Craig
Marks
|
Finance;
Fixed Income
|
+44
7881 615 764
|
Jennifer
Kretzmann
|
Retail
Investors
|
+44 203
749 5824
|
US
toll-free
|
|
+1 866
381 7277
|
Adrian Kemp
Company Secretary
AstraZeneca PLC
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
Date:
31 October
2018
|
By: /s/
Adrian Kemp
|
|
Name:
Adrian Kemp
|
|
Title:
Company Secretary
|